Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of safety, tolerability, pharmacokinetics (PK) and efficacy of two strengths of MH004 Cream in adolescents (ages 12 years and above) and adults with mild-to-moderate atopic dermatitis

Next Previous
Trial Profile

A phase 2 study of safety, tolerability, pharmacokinetics (PK) and efficacy of two strengths of MH004 Cream in adolescents (ages 12 years and above) and adults with mild-to-moderate atopic dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib etocomil (Primary)
  • Indications Atopic dermatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Minghui Pharmaceutical (Shanghai)

Most Recent Events

  • 20 Apr 2023 New trial record
  • 14 Apr 2023 Primary endpoint (mean percentage changes from baseline in EASI score) has been met, according to a Minghui Pharmaceutical Inc. Media Release.
  • 14 Apr 2023 According to a Minghui Pharmaceutical Inc. Media Release, positive top-line results of this study were presented.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top